Profusa Bolsters European Commercial Network with New French Distributor, MedSell
Profusa (NASDAQ: PFSA) announced a distribution partnership with MedSell to commercialize Lumee™ Oxygen tissue monitoring in France, expanding European coverage that now reaches roughly 200,000 CLI cases annually across the EU.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Profusa (NASDAQ: PFSA) announced a distribution partnership with MedSell to commercialize Lumee™ Oxygen tissue monitoring in France, expanding European coverage that now reaches roughly 200,000 CLI cases annually across the EU. The agreement complements a clinical collaboration with Pr. Yann Gouëffic, whose practices represent about 8% of CLTI cases in France. Profusa plans European commercialization beginning 2Q 2026 and targeting US commercialization in 2027, and provided revenue targets of $0.5–2M in 2026, $9–13M in 2027, and a potential goal of $200–250M by 2030.
Positive
- European reach: ~200,000 annual CLI cases represented
- French distribution via MedSell for hospitals and clinics
- KOL adoption covering ~8% of France CLTI cases
- 2027 revenue guidance of $9–13M
Negative
- Low near-term revenue guide: $0.5–2M for 2026
- US commercialization targeted only in 2027, delaying US revenue
Details
News Market Reaction – PFSA
On Dec 31, the day this news came out, PFSA closed 13.96% below the previous close.
Data tracked by StockTitan Argus for the Dec 31 session.
Key Figures
- Annual CLI cases
- 200,000 cases
- Approximate annual CLI cases reached in EU via distributors
- French CLTI share
- 8%
- Approximate share of all CLTI cases covered by Pr. Gouëffic’s practices in France
- 2030 revenue target
- $200–$250 million
- Management’s potential revenue goal by 2030
- 2026 revenue potential
- $0.5–$2 million
- Management’s potential revenue range for 2026
- 2027 revenue potential
- $9–$13 million
- Management’s potential revenue range for 2027
- EU commercialization timing
- 2Q 2026
- Planned start of European Lumee Oxygen commercialization
- U.S. Lumee timing
- 2027
- Goal to address the U.S. Lumee oxygen opportunity
Historical Context
-
Restructured senior secured convertible notes to increase floor and reduce dilution risk.
-
U.S. Lumee study met primary endpoints in PAD patients with up to 12-month follow-up.
-
Acceptance of U.S. Lumee pilot study abstract for LINC 2026 presentation.
-
Late Breaking Clinical Trial Update on Lumee oxygen monitoring at Paris Vascular Insights.
-
Q3 highlights with debt reduction, PIPE and ELOC funding, and long-term revenue targets.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
critical limb threatening ischemia medical
endovascular medical
tissue oxygen perfusion medical
outpatient care medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now reach approximately 200,000 annual CLI cases in the European Union
Agreement complements KOL collaboration with Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris that accounts for approximately
BERKELEY, Calif, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a new distributor partnership in France with MedSell. MedSell is a French company that specializes in the commercialization and distribution of innovative medical devices within the French healthcare market by leveraging tailored commercial, marketing, and market-entry support services. As part of its portfolio, Profusa’s new partner will commercialize Lumee Oxygen tissue monitoring in France in both hospital settings and outpatient care, especially in wound care and healing clinics addressing patients with complex and chronic wounds.
Benoit Salaün, Pharm.D., Ph.D., MedSell General Manager, said, “Our collaboration with Profusa stems from our particular interest in Lumee Oxygen tissue monitoring for the large population of patients in France with Critical Limb Threatening Ischemia (CLTI). The device enables the measurement of tissue oxygen perfusion before revascularization, during endovascular or open surgical procedures, and throughout follow-up in hospitals or wound care clinics. We believe Lumee Oxygen tissue monitoring meets a critical unmet clinical need and can bring significant added value to clinicians by supporting decision-making and patient monitoring across the entire treatment pathway.”
With MedSell, Profusa builds upon previously announced distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now represent more than 200,000 CLI cases annually in the European Union. Further, the distribution partnership with MedSell complements Profusa’s previously announced collaboration with Yann Gouëffic, M.D., Ph.D., professor of vascular surgery in the Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris, France and a leading surgeon in the field of critical limb threatening ischemia (CLTI). Under the agreement, Pr. Gouëffic adopts Lumee™ oxygen monitoring technology in his practice and in clinical studies that advance application of Lumee for home monitoring. Pr. Gouëffic and his associated practices account for approximately
"We are focused on executing on our commercial strategies, including plans to potentially achieve
About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Contacts
Investor and Media Contacts
email: info@coreir.com
phone: 1 (212) 655-0924
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.